Dr Reddy's Laboratories (Dr Reddy's Laboratories) Net Change in Cash

: $16 Mil (TTM As of Dec. 2023)

View and export this data going back to 2001. Start your Free Trial

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Dr Reddy's Laboratories's Net Change in Cash for the three months ended in Dec. 2023 was $-72 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2023 was $16 Mil.

Dr Reddy's Laboratories Net Change in Cash Historical Data

The historical data trend for Dr Reddy's Laboratories's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dr Reddy's Laboratories Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Net Change in Cash

-4.52

-3.57

176.57

0.42

-110.29

Dr Reddy's Laboratories Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Net Change in Cash																-34.36	-5.84	17.62	75.92	-72.07

Dr Reddy's Laboratories Net Change in Cash Calculation

Dr Reddy's Laboratories's Net Change in Cash for the fiscal year that ended in Mar. 2023 is calculated as

Net Change in Cash	=	Cash Flow from Operations	+	Cash Flow from Investing	+	Cash Flow from Financing	+	Effect of Exchange Rate Changes
	=	715.662	+	-502.914	+	-326.512	+	3.477
	=	-110

Dr Reddy's Laboratories's Net Change in Cash for the quarter that ended in Dec. 2023

Net Change in Cash = Cash Flow from Operations + Cash Flow from Investing + Cash Flow from Financing + Effect of Exchange Rate Changes

= 56.898 + -194.345 + 63.444 + 1.934

= -72

Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $16 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Dr Reddy's Laboratories Net Change in Cash Related Terms
Thank you for viewing the detailed overview of Dr Reddy's Laboratories's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Dr Reddy's Laboratories (Dr Reddy's Laboratories) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Dr Reddy's Laboratories Ltd (NYSE:RDY) » Definitions » Net Change in Cash

Comparable Companies

BOM:532321 BOM:543904 NSE:DIVISLAB NSE:TORNTPHARM BOM:500257 NSE:AUROPHARMA NSE:ALKEM BOM:524494 BOM:532331 BOM:532296 ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XTAE:TEVA TSE:4507 VTRS NBIX XSWX:SDZ

Traded in Other Exchanges

DRREDDY:India 500124:India RDDA:Germany RDDA:Germany R1DY34:Brazil

Address

8-2-337, Road No. 3, Banjara Hills, Hyderabad, TG, IND, 500 034

Website

https://www.drreddys.com

Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (22% of its generics sales), Russia (12%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.

Dr Reddy's Laboratories (Dr Reddy's Laboratories) Headlines

From GuruFocus

Dr. Reddy's Laboratories and MediCane Health Announce the Launch of Medical Cannabis Products in Germany
By Business Wire Business Wire • 04-01-2022

Dr. Reddy's becomes first Indian pharma company to debut on the Dow Jones Sustainability World Index
By Business Wire • 12-14-2023

Dr. Reddy's Laboratories announces the launch of Difluprednate Ophthalmic Emulsion 0.05% in the U.S. Market
By Business Wire Business Wire • 01-27-2023

Dr. Reddy's successfully completes full set of clinical studies of its rituximab biosimilar for filing in the U.S., Europe
By Business Wire Business Wire • 01-20-2023

Dr. Reddy's Laboratories Announces the Launch of Regadenoson Injection 0.4 mg/5 mL in the U.S.
By Business Wire Business Wire • 05-05-2023

Dr. Reddy's Laboratories Announces the Launch of Its Authorized Generic Version of VASOSTRICT� (vasopressin injection, USP) Vials in the U.S. Market
By Business Wire Business Wire • 02-09-2022

Dr. Reddy's included in Bloomberg Gender-Equality Index for the 6th year in a row and S&P Global's Sustainability Yearbook for the 3rd year
By Business Wire Business Wire • 02-08-2023

Dr. Reddy's Announces the First-to-Market Launch of Over-the-Counter, Store-Brand Equivalent of Allegra-D� 24 Hr in the U.S. Market
By Business Wire Business Wire • 07-22-2022

Dr. Reddy's Laboratories announces the launch of Bortezomib for Injection, 3.5 mg Single-Dose Vial in the U.S. Market
By Business Wire Business Wire • 07-27-2022

Dr. Reddy's Q1 FY24 Financial Results
By Business Wire • 07-26-2023